IGC Pharma Nears Key Alzheimer’s Trial Milestone With Fast-Acting Therapy

IGC Pharma (NYSE American: IGC) has reached 80% enrollment in its Phase 2 CALMA clinical trial, targeting agitation in Alzheimer’s patients—a major and often disruptive symptom affecting both patients and caregivers. The company expects to complete enrollment soon, followed by data lock and a top-line readout within months.

Early data suggests the company’s investigational therapy may deliver results within two weeks, significantly faster than current treatments. IGC is also expanding into psychedelic research, exploring psilocybin-based therapies for related conditions such as anxiety and depression in Alzheimer’s patients.

#IGCPharma
#Alzheimers
#ClinicalTrials
#Biotech
#MentalHealth
#Neuroscience
#DrugDevelopment
#Psychedelics
#HealthcareInnovation
#MedicalResearch
#NeurodegenerativeDisease
#Pharmaceuticals
#Innovation
#JaneKing
#NewsOut